Key Takeaways
- Fucoidan is generally well-tolerated in clinical studies at standard doses. Across multiple trials in cancer patients, healthy adults, and elderly populations, researchers have consistently reported low adverse event rates with no serious adverse events attributed to fucoidan.
- The most important drug interaction is with anticoagulant medications. Fucoidan has documented blood-thinning properties — if you take warfarin, aspirin, clopidogrel, or similar drugs, consult your prescribing physician before supplementing.
- Digestive discomfort is the most commonly reported side effect, though clinical trials report it at low frequency. Taking fucoidan with food and starting at a lower dose significantly reduces this risk.
- A pilot clinical study found that oral fucoidan's anticoagulant effect may be weaker than laboratory studies suggest, due to low intestinal bioavailability — but clinical caution with blood thinners remains appropriate.
- Japanese safety research fills an important gap: dedicated safety trials using standardized Mozuku and Gagome Kombu (Kjellmaniella crassifolia) fucoidan extracts — the species used in most Japanese supplements — provide the most relevant safety data for supplement users.
- Specific populations should exercise caution: people on anticoagulants, those with thyroid conditions, pregnant or nursing women, and individuals with seaweed allergies should discuss fucoidan with their healthcare provider before starting.
You've done your homework on fucoidan. You know it's a seaweed-derived compound with genuine research behind it, and you're considering adding it to your supplement routine. But before you do, you want an honest answer to the question every thoughtful supplementer asks: what are the side effects of fucoidan, and are there any situations where I should avoid it?
Most articles on this topic fall into one of two traps. Some downplay the risks entirely — "fucoidan is natural seaweed, how could it cause problems?" Others issue vague, uncontextualized warnings that leave you more confused than when you started. Neither serves you well.
This guide takes a different approach. We reviewed the published clinical evidence — including Japanese safety trials that most international guides overlook — to give you a complete, evidence-grounded safety profile. We cover the common side effects, the specific populations who need to be careful, the drug interactions that actually matter, and what years of clinical research across diverse populations actually show about fucoidan's long-term safety record.
If you're already familiar with fucoidan's benefits and mechanisms, our complete guide to fucoidan covers that in depth. This article focuses exclusively on the safety picture.
What Is Fucoidan?
Fucoidan is a sulfated polysaccharide — a long-chain carbohydrate with sulfate groups attached — found naturally in the cell walls of several species of brown seaweed. The sulfate groups are responsible for most of fucoidan's biological activities, including its documented immune-modulating and anticoagulant properties. [1]
The main seaweed species used in supplements include Okinawa Mozuku (Cladosiphon okamuranus), Gagome Kombu (Kjellmaniella crassifolia) from Hokkaido, Japan, Undaria pinnatifida (Mekabu/Wakame), and Fucus vesiculosus (a common Atlantic/European species). Importantly, the sulfation pattern — and therefore the biological activity and safety profile — differs between species. This species distinction matters when interpreting safety research, as we explain in the Japanese research section below. [1]
For a full overview of fucoidan's mechanisms and health applications, see our complete guide to fucoidan.
Common Side Effects of Fucoidan
Digestive Upset: Moderate Evidence
Digestive discomfort is the most frequently mentioned side effect of fucoidan supplementation, though it's important to put the frequency in context. In clinical trials assessing fucoidan's safety — including one that specifically examined the effects of consuming four times the standard daily dose for four weeks in healthy adults — researchers observed no adverse events or laboratory abnormalities. [4]
That said, as with most dietary supplements that contain complex carbohydrates, some people experience mild, transient gastrointestinal symptoms — particularly nausea, loose stools, or stomach discomfort — especially at higher doses or when starting supplementation. These effects are dose-dependent and typically resolve with lower doses or taking fucoidan with food.
A randomized controlled trial evaluating low-molecular-weight fucoidan in patients with atopic dermatitis reported no severe adverse events in either the treatment or placebo group. [9] Taken together, the clinical picture suggests that digestive side effects, when they occur, tend to be mild and manageable rather than a reason to discontinue supplementation.
Blood-Thinning Effects: Moderate Evidence (with Important Nuance)
Fucoidan has well-documented anticoagulant and antithrombotic properties — this is a pharmacological mechanism, not just a theoretical warning. In laboratory and animal studies, fucoidan has demonstrated anticoagulant activity similar in some ways to heparin, with the ability to inhibit certain clotting factors and reduce platelet aggregation. [2]
Here is where an important nuance comes in: the extent to which this laboratory effect translates to real-world anticoagulant risk when fucoidan is taken orally is less certain than many guides imply. A pilot clinical study published in the journal Blood Coagulation & Fibrinolysis that specifically evaluated oral fucoidan's anticoagulant activity in humans found that "the in-vivo effect of fucoidan on hemostasis was not obvious, probably due to low intestinal bioavailability" — with oral bioavailability estimated at less than 0.6% in humans. [5]
This doesn't mean the anticoagulant warning should be ignored — the potential consequences of increased bleeding are serious enough that caution remains appropriate, and clinical guidance is clear on this point. But it does mean that for people who are not on anticoagulant medications and have no bleeding disorder, the real-world blood-thinning risk from standard supplemental doses of fucoidan is likely lower than preclinical research alone would suggest.
Allergic Reactions: Preliminary Evidence
Allergic reactions to fucoidan supplements are considered rare in available literature, and large-scale clinical trials have reported low allergic event rates. The populations most likely to be at risk are those with known seaweed allergies.
One question that comes up frequently is whether people with shellfish allergies can take fucoidan safely. The allergy mechanism is different: shellfish allergies are typically protein-based, while seaweed-related reactions often relate to iodine sensitivity rather than protein cross-reactivity. However, for anyone with a complex marine allergy history, a conversation with an allergist before starting fucoidan is worthwhile. [12]
Iodine Content and Thyroid Effects: Moderate Evidence (for Thyroid Patients)
Because fucoidan is derived from seaweed, it naturally contains iodine. The amount varies by species and extraction method — standardized fucoidan extracts generally contain less iodine than raw seaweed powder supplements, since the extraction process concentrates the fucoidan fraction specifically.
For most people, the iodine contribution from fucoidan supplements at standard doses is modest. But for individuals managing thyroid conditions — both hypothyroidism (where iodine excess can disrupt medication-controlled hormone balance) and hyperthyroidism (where additional iodine can exacerbate symptoms) — any change in dietary iodine intake warrants attention. Japanese clinical guidance specifically identifies thyroid patients as a population requiring caution with fucoidan supplementation. [25]
A practical consideration: many fucoidan supplements do not disclose their iodine content per serving. Thyroid patients should actively look for products that do — or discuss this with their endocrinologist before starting.
Who Should Not Take Fucoidan?
No absolute contraindications to fucoidan have been established in clinical trials — but several groups should approach it with caution or avoid it without healthcare provider guidance.
People Taking Blood Thinners
This is the most important safety warning, consistently endorsed by medical institutions. Memorial Sloan Kettering Cancer Center (MSKCC), one of the world's leading cancer treatment institutions, explicitly states: "Talk with your healthcare provider if you're taking a blood thinner, such as warfarin (Coumadin® and Jantoven®). Fucoidan may increase your risk of bleeding." [12]
This warning applies not only to warfarin but also to aspirin (especially at therapeutic doses), clopidogrel (Plavix), heparin, and other anticoagulant or antiplatelet medications. Even if the clinical evidence suggests that oral bioavailability limits the anticoagulant effect in practice, the potential consequences of amplified bleeding risk — particularly for patients whose anticoagulation is carefully managed — make this an interaction you must discuss with your prescribing physician, not manage on your own.
MSKCC also recommends stopping fucoidan at least two weeks before any scheduled surgery, consistent with general pre-operative supplement guidelines.
People with Thyroid Disorders
As described above, thyroid patients — particularly those on medication for hypothyroidism or hyperthyroidism — should consult their endocrinologist before starting fucoidan due to the iodine content in seaweed-derived supplements. The key practical step is to determine the iodine content of the specific product and factor it into your total daily iodine management.
Pregnant and Nursing Women
No human safety data exists for fucoidan use during pregnancy or lactation. Every major Japanese clinical trial on fucoidan has explicitly excluded pregnant and nursing women from enrollment — not because harm has been demonstrated, but because it simply hasn't been studied. Animal studies have not revealed teratogenic effects, but the absence of human data means the standard precautionary guidance applies: avoid fucoidan during pregnancy and nursing unless under direct physician supervision.
Individuals with Seaweed or Marine Allergies
Those with documented seaweed allergies, or anyone with a history of reactions to multiple marine organisms, should discuss fucoidan with an allergist before trying it. The cross-reactivity risk is not well-quantified in published literature, but caution is appropriate.
People with Autoimmune Conditions on Immunosuppressants
Fucoidan has immune-modulating properties. While this is one of its potential benefits, it creates a theoretical interaction concern for people taking immunosuppressant medications — such as those prescribed after organ transplants or for autoimmune diseases. The evidence is theoretical and preclinical, but it's a relevant reason to disclose fucoidan supplementation to any prescribing physician managing immune-related conditions. [14]
Fucoidan Drug Interactions
Clinical evidence for fucoidan drug interactions is more limited than for pharmaceuticals — most data comes from preclinical (laboratory and animal) studies, with human data focused primarily on cancer therapy contexts. Here is what is currently known.
Anticoagulant and Antiplatelet Drugs: Most Documented
The interaction with blood-thinning medications is the most documented and clinically important. The theoretical mechanism — additive anticoagulant effects — is pharmacologically sound, even if oral bioavailability questions have nuanced its real-world impact. Specific medications to be aware of include warfarin (Coumadin/Jantoven), heparin, aspirin at therapeutic doses, clopidogrel (Plavix), and non-steroidal anti-inflammatory drugs (NSAIDs) used regularly.
Diabetes Medications: Preliminary Evidence
Fucoidan has shown blood glucose-lowering effects in some preclinical studies. This creates a theoretical potential for additive hypoglycemic effects in people taking insulin or oral diabetes medications. The evidence is preliminary and has not been studied in human clinical trials, but people managing diabetes with medication should mention fucoidan to their prescribing physician. [14]
CYP450 Drug Metabolism: Species-Specific Concern
Fucus vesiculosus — a European and Atlantic-origin fucoidan species found in many non-Japanese supplements — has been shown in preclinical research to inhibit certain liver enzymes (specifically CYP2C8, CYP2D6, and CYP3A4) involved in metabolizing a wide range of medications. A Japanese safety study published in the Journal of Complementary and Alternative Medicine assessed effects on drug-metabolizing enzymes in a rodent model for Gagome Kombu fucoidan specifically. [22]
This distinction matters: the CYP450 concern is primarily associated with Fucus vesiculosus rather than the Japanese Mozuku or Gagome Kombu species. If you're taking medications that are known to be metabolized through these pathways, be specific about which fucoidan species your supplement contains — and discuss the interaction with your pharmacist or physician.
Stacked Supplements with Anticoagulant Properties: Underappreciated Risk
This is a gap that most safety guides overlook. If you're already taking omega-3 fatty acids, vitamin E, garlic supplements, ginger, or ginkgo biloba — all of which have mild anticoagulant properties — adding fucoidan to the stack could create a cumulative blood-thinning effect that is greater than any single supplement alone. This doesn't mean you can't combine these supplements, but if you're on anticoagulant medication or have a bleeding disorder, your total supplement picture matters as much as any individual ingredient.
Breast Cancer Medications: Reassuring Data
A clinical study examining fucoidan in breast cancer patients taking either tamoxifen or letrozole found no significant pharmacokinetic interactions and reported that patients generally tolerated the combination well, with some reporting reduced pain. [24]
Fucoidan and Chemotherapy: An Important Nuance
When people search for "side effects of fucoidan," some results mention fucoidan in the context of chemotherapy side effects — which can be confusing. Here is the key distinction: several clinical studies suggest that fucoidan may actually reduce certain side effects of chemotherapy, rather than cause them. This is one of the more intriguing areas of fucoidan research.
A study published in Oncology Letters evaluated fucoidan supplementation in colorectal cancer patients undergoing FOLFOX or FOLFIRI chemotherapy regimens. Researchers observed that fucoidan supplementation was associated with reduced general fatigue and appetite loss during treatment — two of the most quality-of-life-limiting side effects of those regimens — compared to patients who did not take fucoidan. No adverse events from fucoidan itself were observed across 6-15 months of supplementation. [8]
A separate clinical study in 20 advanced cancer patients found that fucoidan supplementation significantly reduced levels of inflammatory markers (specifically IL-1β), with stable or improved quality-of-life scores and no adverse events over the supplementation period. [6]
A comprehensive review of clinical studies on fucoidan as adjuvant cancer therapy — published in Clinical and Translational Medicine — described fucoidan's role in alleviating chemotherapy side effects across multiple cancer types as one of its most clinically supported applications. [11]
What this means for you: If you or someone you know is managing cancer treatment, this research is worth knowing about. But it is equally important to understand that all of these studies were conducted in supervised clinical settings under oncologist oversight. Fucoidan is not a cancer treatment, and the research does not suggest it should be used as a self-directed supplement during cancer treatment without explicit guidance from the treating oncologist. Individual clinical situations vary significantly, and the interaction between fucoidan and specific chemotherapy agents may differ from what these studies showed.
How to Minimize Side Effects
For most people, a few straightforward practices significantly reduce the likelihood of experiencing side effects from fucoidan:
Start with a lower dose and increase gradually. The dose-dependency of digestive side effects means that jumping straight to a high dose is the most common trigger. Starting at half the recommended dose for the first one to two weeks allows your digestive system to adapt.
Take fucoidan with food. This is the single most effective practical measure for reducing gastrointestinal side effects. The Japanese NPO Research Institute on Fucoidan specifically notes that fucoidan can be taken at any time of day based on personal preference, but taking it with a meal helps minimize digestive discomfort for those who are sensitive. [15]
Choose standardized fucoidan products over raw seaweed powder. Products standardized for fucoidan content allow you to know your actual fucoidan dose per serving. Raw seaweed powder supplements have highly variable fucoidan concentrations — you may be getting far more or less fucoidan than the label implies, making dosing unreliable and side effect assessment difficult.
Look for products that disclose iodine content. This is especially important for thyroid patients, but it's also useful information for anyone managing their dietary iodine intake. The more transparent a product is about its composition, the more you can make informed decisions.
Disclose fucoidan to your healthcare provider — not just if you're on prescription medications, but ideally at any routine check-up. Healthcare providers increasingly need a full picture of supplements, not just pharmaceuticals, to provide accurate guidance.
Clinical safety studies suggest a reasonable margin of safety exists at standard supplemental doses. One study specifically evaluated the effects of consuming four times the standard daily dose for four weeks in healthy adults and found no adverse events or laboratory abnormalities. [4] This provides some reassurance about the margin between standard and potentially problematic doses — though it does not mean that higher doses are indefinitely safe or recommended.
What Clinical Research Shows About Fucoidan Safety
The overall clinical safety picture for fucoidan is consistently favorable. Here is what the published evidence actually shows:
| Study Type | Populations Studied | Duration | Safety Finding |
|---|---|---|---|
| Healthy adults, excessive dose (4× standard) | Healthy adults | 4 weeks | No adverse events or lab abnormalities [4] |
| RCT — atopic dermatitis patients | Patients with skin condition | 12 weeks | "No severe adverse events in either group" [9] |
| Cancer patients, long-term supplementation | Colorectal cancer patients | 6-15 months | No fucoidan-specific adverse events [8] |
| Advanced cancer patients | Mixed cancers | ≥4 weeks | No adverse events, stable/improved QOL [6] |
| Osteoarthritis RCT | Adults with joint condition | Reported | No significant adverse events [7] |
| H. pylori eradication RCT | Adults with H. pylori | Reported | Safety endpoints met [10] |
Comprehensive reviews of available human studies have reached consistent conclusions. A systematic review of fucoidan supplementation in cancer patients across four studies (118 participants) reported no adverse events. [3] A review published in Marine Drugs covering multiple human safety studies concluded: "No interactions or adverse effects were observed with the fucoidan." [2]
What clinical research has NOT yet studied:
- Very long-term use in healthy adults beyond 18 months
- Pediatric populations
- Fucoidan combined with multiple medications simultaneously
- Large-scale randomized trials (n > 200) with safety as the primary endpoint in healthy adults
The honest framing: fucoidan's safety profile is consistently favorable across multiple clinical trials in diverse populations, but the research base is composed of small-to-medium studies rather than large-scale safety trials. The evidence is solid; it is not exhaustive.
Safety Considerations
Fucoidan is not a cure or treatment for any disease. Clinical research supports its use as a dietary supplement in generally healthy adults, but this does not mean it is appropriate for everyone, or that it can replace medical care for any condition.
Signs that warrant stopping supplementation and consulting a healthcare provider:
- Unusual bruising or bleeding you cannot explain
- Skin rash, itching, or swelling shortly after starting fucoidan
- Significant or persistent digestive problems that do not improve with food pairing and dose reduction
- Dizziness or other unusual symptoms
Individual variation matters. Your personal risk profile — existing health conditions, other medications, genetic factors affecting iodine metabolism, seaweed allergy history — shapes your individual safety picture in ways that general guidance cannot fully predict. This is especially true for anyone in the higher-risk groups outlined above.
Not all fucoidan supplements are equivalent. The seaweed species used, extraction method, fucoidan concentration, iodine content, and standardization practices all affect both the safety profile and the clinical relevance of existing research. A raw Fucus vesiculosus powder supplement and a standardized Okinawa Mozuku extract are very different products — and the safety data most applicable to each differs accordingly.
What Japanese Research Reveals About Fucoidan Safety
Japan has produced a body of fucoidan safety research that most international guides don't access — and it fills meaningful gaps in the evidence base.
Safety as a Primary Research Goal
Most internationally published fucoidan research assessed safety as a secondary outcome — researchers were studying fucoidan's benefits in cancer patients or people with specific conditions, and monitored for adverse events along the way. Japanese researchers, by contrast, have conducted dedicated safety-first studies using Japanese-marketed fucoidan products at typical supplemental doses.
A series of studies published in the Journal of Complementary and Alternative Medicine (J-STAGE) evaluated Gagome Kombu (Kjellmaniella crassifolia) fucoidan — one of Japan's two most-studied species — in dedicated safety trials including healthy adults and elderly populations. One study in healthy adults found "no safety-relevant test value deviations in any ingestion group." [21] Another study conducted genotoxicity testing (Ames test, chromosomal aberration, micronucleus assay) and found no mutagenicity. [18]
Why this matters: These studies used standardized fucoidan products that are directly comparable to what Japanese supplement brands sell. Their safety findings are the most clinically relevant for anyone purchasing a Japanese fucoidan supplement.
Elderly-Specific Safety Data
A Japanese clinical study specifically evaluated the safety and immune effects of Gagome Kombu fucoidan in adults aged 60 and older — a population that is largely absent from international fucoidan research. The study found favorable safety findings in this age group, an important finding given that many of fucoidan's primary applications (immune support, general wellness) are particularly relevant to older adults. [17]
Why this matters: The 30-65 age range — Naturacare's core customer demographic — includes people for whom elderly-specific safety data is directly useful, and no comparable study exists in the international literature.
Long-Term Use in Cancer Patients
A separate Japanese clinical study followed cancer patients supplementing with Gagome Kombu fucoidan over a longer term and evaluated safety as a primary endpoint. [19] Meanwhile, a randomized, double-blind, placebo-controlled parallel trial in healthy adults — published recently in Algal Science and Technology — provided additional rigorously controlled safety data for Japanese Gagome fucoidan. [20]
Why this matters: These longer-term studies help bridge the gap between the short clinical trials that dominate international literature and the real-world use patterns of health-conscious supplement users.
Clinical Registration Under MHLW Oversight
Japanese fucoidan safety trials are registered with the Ministry of Health, Labour and Welfare (MHLW) clinical trial registry — such as UMIN000028368, the registration for an Okinawa Mozuku excessive ingestion safety study. [13] This institutional oversight adds a layer of rigor and transparency that is not always present in unregistered supplement safety studies.
Why this matters: When evaluating the trustworthiness of safety data, trial registration is a meaningful signal of methodological transparency. Japanese fucoidan research conducted under MHLW oversight reflects a formal, accountable research framework.
The Species Difference: A Practical Implication
As noted in the drug interactions section, the CYP450 enzyme interaction concern is primarily associated with Fucus vesiculosus — the species found in many Atlantic-sourced, non-Japanese supplements — rather than with Japanese Mozuku or Gagome Kombu fucoidan. Japanese safety research specifically using these Japanese species shows no concerning CYP450 effects at typical supplemental doses. [22]
Why this matters: If you are taking medications that are metabolized by CYP450 enzymes, the fucoidan species in your supplement is a relevant piece of safety information — and Japanese-species products have better-characterized safety profiles on this specific question.
Our Recommendations
Naturacare carries several fucoidan products sourced from Japan's most clinically studied seaweed species. All of these products use standardized fucoidan extracts rather than raw seaweed powder, which provides reliable fucoidan dosing and more consistent safety profiles.
Okinawa Fucoidan by Kanehide Bio
Why We Selected This: Kanehide Bio's Okinawa Fucoidan is derived from Okinawa Mozuku (Cladosiphon okamuranus) — the most extensively studied seaweed species in Japanese clinical fucoidan research, including the dedicated safety trials registered with MHLW. The product uses a high-potency standardized extract, making it easier to know exactly what dose you're working with. For those who want the seaweed species most represented in clinical safety literature, this is our top pick.
View Okinawa Fucoidan by Kanehide Bio →
Fine Fucoidan
Why We Selected This: Fine Japan is a well-regarded Japanese supplement brand with strong distribution and consistent quality. This is a practical option for customers looking for a reliable entry-level Japanese fucoidan supplement with a longer supply (33-day) at an accessible entry point.
Product Comparison
| Product | Format | Best For | Species | Country |
|---|---|---|---|---|
| Okinawa Fucoidan (Kanehide Bio) | Capsule | Research-aligned, high-potency | Cladosiphon okamuranus (mozuku) | Japan (Okinawa) |
| Fine Fucoidan | Capsule | Entry-level, longer supply | Japanese seaweed | Japan |
Conclusion
Fucoidan's clinical safety record is, by the standards of available research, consistently favorable. Across trials in cancer patients, healthy adults, and elderly populations — spanning studies from a few weeks to over a year — researchers have not identified serious adverse events attributed to fucoidan supplementation at standard doses. The most commonly reported side effect, digestive discomfort, is mild and manageable.
The nuance lies in specific populations and contexts. If you are on anticoagulant medication, managing a thyroid condition, pregnant or nursing, or planning surgery, fucoidan requires a conversation with your healthcare provider — not just a cautionary footnote to navigate around. These are not theoretical warnings invented by overcautious regulators; they are grounded in fucoidan's pharmacological properties.
For the majority of healthy adults with no contraindications, the practical guidance is straightforward: choose a standardized Japanese fucoidan product (Mozuku or Gagome Kombu), start at a lower dose, take it with food, and disclose it to your healthcare provider. That approach puts you on solid, evidence-supported ground.
If you're ready to explore fucoidan options, we've curated products that meet those criteria in our recommendations above.
This article is for informational purposes only and does not constitute medical advice. Consult a healthcare professional before starting any supplement regimen, especially if you have existing health conditions or take medications. Statements about dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
Frequently Asked Questions
- Therapeutic Effects of Fucoidan: A Review on Recent Studies
- Therapies from Fucoidan: New Developments
- Effectiveness of Fucoidan on Supplemental Therapy in Cancer Patients: A Systematic Review
- Safety Evaluation of Excessive Ingestion of Mozuku Fucoidan in Humans
- Pilot Clinical Study to Evaluate the Anticoagulant Activity of Fucoidan
- Anti-Inflammatory Effects of Fucoidan in Advanced Cancer Patients
- Fucoidan from Fucus vesiculosus in Reducing Symptoms of Osteoarthritis: A Randomized Placebo-Controlled Trial
- Fucoidan Reduces the Toxicities of Chemotherapy for Patients with Colorectal Cancer
- Low-Molecular-Weight Fucoidan in Atopic Dermatitis: RCT
- Effect of Fucoidan on Gut Microbiota and Clinical Efficacy in H. pylori Eradication: RCT
- Clinical Applications of Fucoidan in Translational Medicine for Adjuvant Cancer Therapy
- Fucoidan — Memorial Sloan Kettering Cancer Center Integrative Medicine
- MHLW Clinical Trial Registry — UMIN000028368 (Okinawa Mozuku Fucoidan Safety Study)
- Fucus vesiculosus (Bladderwrack)
- NPO Research Institute of Fucoidan — FAQ
- Preclinical Evaluation of Safety of Fucoidan Extracts from Undaria pinnatifida and Fucus vesiculosus
- Safety and Immune Function Effects of Gagome Kombu Fucoidan in Elderly
- Genotoxicity Evaluation of Kjellmaniella crassifolia Fucoidan
- Long-Term Safety of Gagome Kombu Fucoidan in Cancer Patients

